News in COVID-19

Use of systemic treatments by cancer patients in England fell in April 2020 but surged in June 2020

Dutch registry findings describe the effect of the SARS-CoV-2 pandemic on cancer patients and the general population

Systemic inflammation is a key driver of mortality in SARS-CoV-2 in cancer patients and biomarkers of inflamation may be used to identify patients at increased risk

Systemic inflammation is a key driver of mortality in SARS-CoV-2 in cancer patients and biomarkers of inflamation may be used to identify patients at increased risk

IgG antibody response to SARS-CoV-2 infection may be comparable among cancer patients and healthy oncology healthcare workers

IgG antibody response to SARS-CoV-2 infection may be comparable among cancer patients and healthy oncology healthcare workers

Interim results of the SAKK 80/20 CaSA study suggest around 18% of Swiss cancer patients with SARS-CoV-2 infection have died

Interim results of the SAKK 80/20 CaSA study suggest around 18% of Swiss cancer patients with SARS-CoV-2 infection have died

Online surveys have revealed the impact of the COVID-19 pandemic on the wellbeing of oncology professionals

Online surveys have revealed the impact of the COVID-19 pandemic on the wellbeing of oncology professionals

Literature analysis suggests that approximately 25% of cancer patients with COVID-19 have died

Low SARS-CoV-2 seroprevalence in both, oncology healthcare workers and cancer patients require continuation of strict safety measures

ESMO has taken the decision due to the uncertain evolution of the Coronavirus pandemic in the Asia-Pacific region and to avoid any risks to the health of the Faculty, delegates and staff.

UK data suggest the risk of acquiring COVID-19 and the severity of infection differ by the type of cancer

Findings from a systematic review and meta-analysis

Haematological malignancy patients with COVID-19 may have a high mortality rate

Findings from a large regional analysis of population that examined the prevalence of cancer and clinical outcomes of viral infection

Findings from a large testing study conducted at a tertiary care hospital in Vienna

An experience of the Drug Development Department of the Gustave Roussy

Restrictive measures to control the spread of COVID-19 have adverse effect on continuation of radiotherapy in patients with cancer

In Annals of Oncology, ESMO’s comprehensive set of recommendations address open questions on how to manage cancer care in the COVID-19 era

Modelling studies predict the outcome of COVID-19 pandemic-related cancer diagnostic delays in England

An interim analysis of survey data in the context of the COVID-19 pandemic

Data from prostate cancer patients in Italy and Finland do not support the hypothesis that androgen deprivation therapy may reduce the risk of SARS-CoV-2 infection

Results from the survey among 5302 cancer patients in the Netherlands

A delay in cancer surgery because of the COVID-19 pandemic may have a significant impact on patient survival

An immunocompromised cancer patient with bone marrow positive for SARS-CoV-2 has developed pancytopenia

A study of cancer patients attending a New York hospital details the rates of hospitalisation, morbidity and mortality associated with COVID-19

Around 10% of cancer patients with suspected or confirmed COVID-19 die within 25 days of being admitted to hospital with symptoms

A study of cancer patients with COVID-19 has identified several risk factors for mortality

More safety data is needed in terms of treatment of symptomatic COVID-19 patients with anticancer drugs

Findings from the MSKCC series

Findings from two Chinese multicentre, retrospective, cohort studies

Results of the UK Coronavirus Cancer Monitoring Project 

The TERAVOLT consortium has identified patient- and treatment-related factors associated with an increased risk for death among thoracic cancer patients with COVID-19 infection

Cancer patients with COVID-19 have specific risk factors that may help contribute to a high rate of mortality

Multifactorial reasons involving patients, general practitioners and the healthcare system

Prostate cancer patients using androgen deprivation therapy might have a lower risk of SARS-CoV-2 infection than other cancer patients

Antibodies more often undetectable in patients who received anticancer treatment in the month prior to testing

Balancing pandemic control with providing continued cancer care

Mortality rates do not appear to be associated with any specific type of treatment or comorbidity in this patient group

Treatment delay of at least 2 months reported in only one quarter of patients

An experience in New York City

Research priorities related to incidence, morbidity and mortality of COVID-19 specific to patients with cancer

An accurate COVID-19 screening model could allow early detection and potentially reduce the risk of severe complications and mortality

Patients with cancer and cancer survivors may have a higher risk of COVID-19 than the general population

A metastatic renal cell carcinoma patient who developed COVID-19 may have benefited from treatment with an IL-6 receptor inhibitor

Guidelines commissioned by the French health authorities

Actions taken at a Chinese cancer hospital may have prevented the spread of SARS-CoV-2 and COVID-19

Situation in the first half of March 2020